Twenty years ago Craig Crews, PhD, and his colleagues, launched a research project that has generated two biotech companies, hundreds of millions of dollars in investments and partnerships, a host of honors for Dr. Crews, and an FDA-approved drug that has helped more than 80,000 patients so far. The project has also inspired drug candidates now in development against prostate cancer and breast cancer, among other diseases. Dr. Crews is confident that all of this is just the beginning. ”It’s a platform technology,” he said of his discovery, “meaning it could be applied to many different cancers and diseases.”
Please click here to read the story at YaleCancerCenter.org.